Ricoh Takes Stake in Biomedical Company, Will Apply Bio-Printing Technology
As with many office-imaging vendors, Ricoh Company of Japan is actively seeking to diversify from its office-imaging and printing into new markets, announcing, for instance, at its April 2019 investors’ conference, that it will expand into industrial printing, 3D printing, and bio-printing and biomedical fields.
To that end, on June 19th, the company announced it’s entered into a strategic business partnership with Elixirgen Scientific, of Baltimore, Maryland, to develop biomedical products and services that support drug discovery based on cell differentiation technology, with Ricoh purchasing a 34.5-percent stake in the company for an undisclosed sum.
Ricoh and Elixirgen Scientific plan to grow this biomedical business into a 20-billion-yen($1.86 billion) business by 2025.
It says that together the two companies will support drug discovery through the manufacture and delivery of cells differentiated from induced pluripotent stem (iPS) cells, cell chips seeded with precisely differentiated cells, and evaluation services for drug responses. As part of the agreement, Ricoh will launch a biomedical business in North America this year.
Elixirgen Scientific owns Quick-Tissue technology that can induce iPS cells and embryonic stem cells to various types of cells directly, with this technology achieving highly efficient and homogeneous cell differentiation within just 10 days.” Ricoh expects that disease-specific iPS cells, which means that iPS cells derived from patients with that disease can be used as a disease model for drug screening. As differentiated cells manufactured in this process have functions close to mature cells, those cells show phenotypes specific to that disease very well.
Ricoh says its bioprinting technology enables precise control of the number and placement of cells using its inkjet print-head technology, which it’s perfected over the last 40 years.
Nobuhiro Gemma, fellow and general manager of for Ricoh Company’s HealthCare Business Group, stated, “We are thrilled to partner with Elixirgen Scientific on this new biomedical development initiative. By combining the technologies from our two companies, it will be possible to produce disease-specific cell chips derived from multiple iPS cell lines, for example. These cell chips can evaluate the diversity of human responses of chemicals at one time in terms of efficacy and toxicity before moving to the clinical trial stage. In the process of drug discovery, this method using the cell chips will greatly improve the entire drug development process because human diversity is considered in the earliest stage.”
Ricoh says it entered the healthcare market with software and services 12 years ago in order to help address issues arising from an aging society, combined with a corresponding reduction in healthcare expenditure, among other operational efficiencies. a
Ricoh’s Gemma further explained: “Ricoh has an established healthcare business with solutions such as its RICOH Regional Health Net; and in the medical imaging area, with its magnetoencephalography solution. We have also been developing technologies such as 3D Bioprinter and reference DNA plates, and with today’s announcement, this agreement establishes Ricoh firmly as a player in the biomedical field.”
- May 2019: Ricoh Introducing Alexa Voice Control for Ricoh Intelligent MFPs
- May 2019: Ricoh Reports Much Improved Earnings for Fiscal Year
- April 2019: Ricoh Canada Launches Ricoh IT Services
- April 2019: Ricoh Targeting Industrial, Textile, 3D Bio-Printing
- January 2019: Ricoh: The Future of Printing is 3D Bioprinting